Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis.
Ina 24-month-old girl with acute lymphoblastic leukemia and invasive aspergillosis, only combination therapy with liposomal amphotericin B and caspofungin achieved a good response. Combination therapy could be a useful treatment option in children with invasive fungal disease, but before it can be routinely recommended, carefully controlled in vivo studies and well-designed randomized clinical trials are needed.
Elanjikal
Ziju
Z
Department of Pediatric Hematology, Children's Hospital III, Frankfurt, Germany.
Sörensen
Jan
J
Schmidt
Helga
H
Dupuis
Wolfgang
W
Tintelnot
Kathrin
K
Jautzke
Günter
G
Klingebiel
Thomas
T
Lehrnbecher
Thomas
T
D000666:Amphotericin B / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy*; D000077336:Caspofungin; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D054714:Echinocandins; D005260:Female; D005500:Follow-Up Studies; D016469:Fungemia / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D055666:Lipopeptides; D008081:Liposomes; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides; D010456:Peptides, Cyclic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000276:immunology; D018570:Risk Assessment; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D054714:Echinocandins; D055666:Lipopeptides; D008081:Liposomes; D010455:Peptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D000077336:Caspofungin